The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to deliver a more substantial reduction in body mass and improve metabolic heal